Royalty Pharma has declared a third-quarter 2026 dividend of $0.235 per share, payable on September 10, 2026.
Quiver AI Summary
Royalty Pharma plc announced its board of directors has approved a dividend of $0.235 per Class A ordinary share for the third quarter of 2026, which will be paid on September 10, 2026, to shareholders on record by August 14, 2026. Established in 1996, Royalty Pharma is recognized as the largest buyer of biopharmaceutical royalties and plays a significant role in funding innovation throughout the biopharmaceutical sector. The company collaborates with a range of entities from academic institutions to major pharmaceutical companies, securing royalties from leading therapies and funding late-stage clinical trials. Currently, Royalty Pharma manages a portfolio that includes royalties from over 35 commercial products and 19 development-stage candidates. For additional information, interested parties can visit their website or contact their investor relations team.
Potential Positives
- Approval of a dividend for the third quarter indicates strong financial health and commitment to returning value to shareholders.
- The dividend payment date and record date provide clarity and assurance to investors regarding their returns.
- Royalty Pharma's extensive portfolio of royalties on leading therapies positions the company favorably within the biopharmaceutical industry.
- The company's role in funding innovation highlights its strategic importance and potential for future growth in biopharmaceuticals.
Potential Negatives
- The announcement of a dividend could indicate limited options for substantial growth reinvestment, potentially signaling a lack of investment opportunities within the company’s current portfolio.
- There is no information provided about the company’s financial health or any recent performance metrics, which may raise concerns among investors about the sustainability of the dividend payment.
- The press release does not disclose any information regarding future projections or strategic plans, which may leave investors feeling uncertain about the company's direction.
FAQ
What is the dividend amount approved by Royalty Pharma for Q3 2026?
The board has approved a dividend of $0.235 per Class A ordinary share for the third quarter of 2026.
When will the dividend be paid to shareholders?
The dividend will be paid on September 10, 2026, to shareholders of record on August 14, 2026.
When was Royalty Pharma founded?
Royalty Pharma was founded in 1996 and has since become a leading buyer of biopharmaceutical royalties.
What types of companies does Royalty Pharma collaborate with?
Royalty Pharma collaborates with academic institutions, research hospitals, non-profits, and various biotechnology and pharmaceutical companies.
How many commercial products are in Royalty Pharma's portfolio?
Royalty Pharma’s portfolio includes royalties on more than 35 commercial products and 19 development-stage candidates.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
EARLY ACCESS
Receive RPRX Data Alerts
Real-time alerts on filings, insider trades, and market signals — before everyone else.
Get Alerts →
$RPRX Insider Trading Activity
$RPRX insiders have traded $RPRX stock on the open market 35 times in the past 6 months. Of those trades, 0 have been purchases and 35 have been sales.
Here’s a breakdown of recent trading of $RPRX stock by insiders over the last 6 months:
- TERRANCE P. COYNE (EVP & CFO) has made 0 purchases and 21 sales selling 551,477 shares for an estimated $24,776,351.
- CHRISTOPHER HITE (EVP & Chairman, Partnering) has made 0 purchases and 6 sales selling 280,000 shares for an estimated $15,504,747.
- MARSHALL URIST (EVP, Research & Investments) has made 0 purchases and 7 sales selling 105,565 shares for an estimated $4,875,761.
- GREGORY NORDEN sold 3,045 shares for an estimated $161,385
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$RPRX Revenue
$RPRX had revenues of $631M in Q1 2026. This is an increase of 11.04% from the same period in the prior year.
You can track RPRX financials on Quiver Quantitative's RPRX stock page.
You can access data on RPRX stock through the Quiver Quantitative API.
$RPRX Hedge Fund Activity
We have seen 296 institutional investors add shares of $RPRX stock to their portfolio, and 221 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MORGAN STANLEY removed 11,702,436 shares (-21.2%) from their portfolio in Q1 2026, for an estimated $555,807,197
- CAPITAL WORLD INVESTORS added 8,036,714 shares (+inf%) to their portfolio in Q1 2026, for an estimated $381,703,731
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 4,485,000 shares (-37.5%) from their portfolio in Q1 2026, for an estimated $213,015,075
- CAPITAL INTERNATIONAL INVESTORS added 3,901,427 shares (+12.5%) to their portfolio in Q1 2026, for an estimated $185,298,275
- ROYAL LONDON ASSET MANAGEMENT LTD added 3,628,670 shares (+2019.5%) to their portfolio in Q1 2026, for an estimated $172,343,681
- CITADEL ADVISORS LLC removed 2,592,796 shares (-49.2%) from their portfolio in Q1 2026, for an estimated $123,144,846
- JANE STREET GROUP, LLC removed 2,547,027 shares (-51.5%) from their portfolio in Q1 2026, for an estimated $120,971,047
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$RPRX Analyst Ratings
Wall Street analysts have issued reports on $RPRX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- JP Morgan issued a "Overweight" rating on 05/07/2026
To track analyst ratings and price targets for $RPRX, check out Quiver Quantitative's $RPRX forecast page.
$RPRX Price Targets
Multiple analysts have issued price targets for $RPRX recently. We have seen 4 analysts offer price targets for $RPRX in the last 6 months, with a median target of $60.5.
Here are some recent targets:
- Chris Schott from JP Morgan set a target price of $58.0 on 05/07/2026
- Geoff Meacham from Citigroup set a target price of $66.0 on 05/07/2026
- Ashwani Verma from UBS set a target price of $57.0 on 04/21/2026
- Terence Flynn from Morgan Stanley set a target price of $63.0 on 04/10/2026
Full Release
NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2026 of $0.235 per Class A ordinary share.
The dividend will be paid on September 10, 2026, to shareholders of record at the close of business on August 14, 2026.
About Royalty Pharma plc
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, Servier’s Voranigo, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, and 19 development-stage product candidates. For more information, visit
www.royaltypharma.com
.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6772
ir@royaltypharma.com
Read full article here »
View the Zacks #1 Rank List
Royalty Pharma Announces Third Quarter 2026 Dividend of $0.235 per Class A Ordinary Share
Royalty Pharma has declared a third-quarter 2026 dividend of $0.235 per share, payable on September 10, 2026.
Quiver AI Summary
Royalty Pharma plc announced its board of directors has approved a dividend of $0.235 per Class A ordinary share for the third quarter of 2026, which will be paid on September 10, 2026, to shareholders on record by August 14, 2026. Established in 1996, Royalty Pharma is recognized as the largest buyer of biopharmaceutical royalties and plays a significant role in funding innovation throughout the biopharmaceutical sector. The company collaborates with a range of entities from academic institutions to major pharmaceutical companies, securing royalties from leading therapies and funding late-stage clinical trials. Currently, Royalty Pharma manages a portfolio that includes royalties from over 35 commercial products and 19 development-stage candidates. For additional information, interested parties can visit their website or contact their investor relations team.
Potential Positives
Potential Negatives
FAQ
What is the dividend amount approved by Royalty Pharma for Q3 2026?
The board has approved a dividend of $0.235 per Class A ordinary share for the third quarter of 2026.
When will the dividend be paid to shareholders?
The dividend will be paid on September 10, 2026, to shareholders of record on August 14, 2026.
When was Royalty Pharma founded?
Royalty Pharma was founded in 1996 and has since become a leading buyer of biopharmaceutical royalties.
What types of companies does Royalty Pharma collaborate with?
Royalty Pharma collaborates with academic institutions, research hospitals, non-profits, and various biotechnology and pharmaceutical companies.
How many commercial products are in Royalty Pharma's portfolio?
Royalty Pharma’s portfolio includes royalties on more than 35 commercial products and 19 development-stage candidates.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$RPRX Insider Trading Activity
$RPRX insiders have traded $RPRX stock on the open market 35 times in the past 6 months. Of those trades, 0 have been purchases and 35 have been sales.
Here’s a breakdown of recent trading of $RPRX stock by insiders over the last 6 months:
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$RPRX Revenue
$RPRX had revenues of $631M in Q1 2026. This is an increase of 11.04% from the same period in the prior year.
You can track RPRX financials on Quiver Quantitative's RPRX stock page.
You can access data on RPRX stock through the Quiver Quantitative API.
$RPRX Hedge Fund Activity
We have seen 296 institutional investors add shares of $RPRX stock to their portfolio, and 221 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$RPRX Analyst Ratings
Wall Street analysts have issued reports on $RPRX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
To track analyst ratings and price targets for $RPRX, check out Quiver Quantitative's $RPRX forecast page.
$RPRX Price Targets
Multiple analysts have issued price targets for $RPRX recently. We have seen 4 analysts offer price targets for $RPRX in the last 6 months, with a median target of $60.5.
Here are some recent targets:
Full Release
NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2026 of $0.235 per Class A ordinary share.
The dividend will be paid on September 10, 2026, to shareholders of record at the close of business on August 14, 2026.
About Royalty Pharma plc
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, Servier’s Voranigo, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, and 19 development-stage product candidates. For more information, visit www.royaltypharma.com .
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6772
ir@royaltypharma.com
Read full article here »